Premium
Valproate modulates glucose metabolism in patients with epilepsy after first exposure
Author(s) -
Rakitin Aleksei,
Kõks Sulev,
Haldre Sulev
Publication year - 2015
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/epi.13114
Subject(s) - hyperinsulinemia , epilepsy , medicine , endocrinology , insulin , insulin response , carbohydrate metabolism , glucose tolerance test , plasma glucose , insulin resistance , psychiatry
Summary Valproate ( VPA ) treatment has been reported to be associated with weight gain and metabolic changes, such as hyperinsulinemia. The question of whether hyperinsulinemia and other metabolic changes are consequences of increased weight, or are instead direct results of VPA treatment, remains a matter of debate. The aim of the current study was to explore the influence of VPA treatment on glucose and insulin levels during the oral glucose tolerance test ( OGTT ) directly following the first intravenous ( IV ) administration. Sixteen patients (18–46 years old) with newly diagnosed epilepsy underwent an OGTT with 75 g glucose prior to the start of VPA treatment, as well as directly following the first IV VPA administration. We observed that plasma glucose levels during the 120 min of OGTT session following infusion of VPA were significantly lower than those measured during OGTT without VPA treatment (mean ± standard deviation [SD] 4.28 ± 0.94 mmol/l vs. 4.75 ± 1.09 mmol/l respectively, p = 0.038). However, blood concentrations of insulin and C‐peptide did not differ significantly between the two measurements. This is the first study to show a potential acute glucose‐lowering effect of VPA during OGTT in patients with newly diagnosed epilepsy.